Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Amgen · Phase 1 · Completed · Enrollment 348

NCT07226778

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide SC Presentation 1Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide SC Presentation 2Obesity or overweightn/rn/rn/rn/r